GeoVax Strengthens Scientific Advisory Board with Global Vaccine Experts
TL;DR
GeoVax strengthens its competitive edge by adding top vaccine and immunology experts to its advisory board, accelerating development of vaccines for underserved populations and cancers.
GeoVax expanded its Scientific Advisory Board with experts in vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised medicine to guide its MVA platform and clinical strategy.
GeoVax's enhanced advisory board focuses on developing vaccines that protect vulnerable populations in low-income countries and immunocompromised patients, aiming for more equitable global health outcomes.
GeoVax assembled a dream team of vaccine experts including Oxford's Teresa Lambe and T-cell mapping pioneer Alessandro Sette to tackle infectious diseases and cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, announced the addition of five internationally recognized experts to its Scientific Advisory Board. The strategic expansion aims to support the company's development efforts with its MVA vector platform for vaccines targeting biothreat pathogens and vulnerable populations including those in low- and middle-income countries and immunocompromised patients.
The newly appointed members join Professor Teresa Lambe, whose appointment was previously announced. Dr. Alessandro Sette, Director of Biological Sciences at the Center for Infectious Disease and Vaccine Research at La Jolla Institute for Immunology, brings expertise in T-cell epitope mapping and immune correlates of protection. He leads the NIH Immune Epitope Database and has defined T-cell immunity across SARS-CoV-2, Mpox, and Ebola.
Professor Lance Turtle, Chair in Immunity and Infectious Diseases at the University of Liverpool and Royal Liverpool Hospital, specializes in viral pathogenesis and post-infection immune recovery. His research provides translational insights into long-term immunity and emerging pathogen preparedness.
Professor Thushan I. de Silva, Professor of Infectious Diseases and Immunology at the University of Sheffield, is an expert in human viral immunology, vaccine responses, and global immunosurveillance. He leads studies across Europe, Asia, and Africa evaluating population-level vaccine immunity and viral evolution.
Dr. Joshua A. Hill, Associate Professor at the University of Washington School of Medicine and Fred Hutchinson Cancer Center, focuses on vaccine response in immunocompromised and transplant patients. His work aligns with GeoVax's emphasis on protecting high-risk, underserved populations.
David Dodd, GeoVax Chairman and CEO, stated that assembling this exceptional team strengthens the company's position at the forefront of vaccine innovation. Their combined experience from antigen design to human immunology and clinical translation aligns with GeoVax's mission to deliver durable, broad-spectrum protection to global and immunocompromised populations.
Dr. Kelly McKee, Chief Medical Officer, noted that the addition ensures clinical strategy is guided by cutting-edge immunology insight and global research expertise. The collaboration will be instrumental as GeoVax advances vaccines and immunotherapies designed to protect vulnerable populations, particularly those in low and middle income countries and immunocompromised patients underserved by traditional approaches.
Dr. Mark Newman, Chief Scientific Officer, stated that the expanded SAB strengthens multiple aspects of the company's R&D platform. With input from respected scientific leaders, GeoVax can ensure its vaccine and immunotherapy candidates deliver real-world impact. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster vaccine in patients with chronic lymphocytic leukemia, and a more robust COVID-19 booster among healthy patients who previously received mRNA vaccines. For more information about clinical trials and updates, visit https://www.geovax.com.
Curated from NewMediaWire
